J&J subsidiary licensing HIV drug in India
Irish-based Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson that has offices in Yardley, said today that it has signed a royalty-free, non-exclusive license agreement with Emcure Pharmaceuticals Limited of India to distribute an HIV drug in India.
Irish-based Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson that has offices in Yardley, said today that it has signed a royalty-free, non-exclusive license agreement with Emcure Pharmaceuticals Limited of India to distribute an HIV drug in India.
Tibotec said that it has been working with regulatory authorities in India to register darunavir. If approved, darunavir, co-administered with ritonavir and with other antiretroviral agents, is expected to be a treatment for adults with human immunodeficiency virus, which causes AIDS.
Tibotec works with local companies in developing countries to provide access to its antiretrovirals. Last year, it provided a royalty-free voluntary license to Aspen Pharmaceutical to make the drug available in sub-Saharan Africa. In total, Darunavir is registered in 79 countries worldwide.